Table 5 Diagnostic Performance of Restaging MR Imaging and PET/CT after Neoadjuvant Chemotherapy for Prediction of Advanced ALN metastases.
Imaging modalities | AUC | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|
MR imaging | 0.792 | 83.3% | 75.0% | 29.4% | 97.3% |
PET/CT | 0.729 | 58.3% | 87.5% | 36.8% | 94.4% |
Combined MR imaging plus PET/CT | 0.849 | 100.0% | 69.8% | 29.3% | 100.0% |
